TITLE

ORAMED AWARDED NIS 3.1 MILLION GRANT FROM ISRAEL

PUB. DATE
September 2009
SOURCE
Worldwide Biotech;Sep2009, Vol. 21 Issue 9, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article announces that Oramed Pharmaceuticals Inc. was awarded with a 3.1 million Shekels grant by the Ofiice of Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel in September 2009.
ACCESSION #
43826761

 

Related Articles

  • IMMUNE Granted US$1 Million (NIS 3.8M) by Israel.  // Worldwide Biotech;Mar2012, Vol. 24 Issue 3, p1 

    The article announces that the Israeli Office of the Chief Scientist (OCS) granted 1 million U.S. dollars to support two drug development products of Immune Pharmaceuticals.

  • Medgenics Awarded Grant from the Israeli Office of the Chief Scientist.  // Biomedical Market Newsletter;8/12/2011, Vol. 21, p226 

    The article reports that Medgenics Inc. has received 3.0 million New Israeli Shekel (NIS) grant from the Office of the Chief Scientist (OCS) of the Israel Ministry of Industry, Trade, and Labor. It states that OCS grant is given to companies with innovative technology, potential market...

  • Medgenics Awarded $2.2 Mln Grant from the Israeli Office of the Chief Scientist.  // Biomedical Market Newsletter;5/12/2012, Vol. 21, p1 

    The article informs that Medgenics Medical Israel Ltd. was awarded a government grant of 8.1 million New Israeli Shekel from the Office of the Chief Scientist at the Israel Ministry of Industry, Trade & Labor. The grant will be used to cover research & development expenses and for the...

  • Progress Made on Oral Insulin.  // Chain Drug Review;6/7/2010, Vol. 32 Issue 10, p228 

    The article reports on the results of the clinical trial of Oramed Pharmaceuticals Inc. on its flagship oral insulin capsule, ORMD-0801, in Jerusalem.

  • Oramed Pharmaceuticals Chosen to Present at XVI Intl Symposium on Atherosclerosis.  // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1 

    The article informs that the International Symposium on Atherosclerosis to be held from March 25-29, 2012 in Sydney, New South Wales, will feature the presentation of Oramed Pharmaceuticals Inc.

  • Other News To Note.  // BioWorld Today;7/8/2010, Vol. 21 Issue 130, p2 

    This section offers news briefs on the pharmaceutical industry as of July 2010. The National Institutes of Health has awarded 600,000 U.S. dollars to Dynavax Technologies Corp. for a study on the feasibility of developing a vaccine against human papillomavirus (HPV). Oramed Pharmaceuticals Inc....

  • American Diabetes Association.  // BioWorld Today;6/29/2010, Vol. 21 Issue 124, p7 

    The article reports on the results presented by Oramed Pharmaceuticals Inc. concerning two of its recently completed trials, the Phase IIa study testing its flagship ORMD-0801 oral insulin capsule in Type I diabetes patients when administered just before a standard meal, and a summary of its...

  • ORAMED COMPLETES FDA PHASE 2A CLINICAL TRIAL.  // Worldwide Biotech;Apr2014, Vol. 26 Issue 4, p7 

    The article reports on the completion by Oramed Pharmaceuticals Inc. to its Phase 2a clinical trials for its ORMD-0801 oral insulin capsule for type 2 diabetes under the U. S. Food and Drug Administration (FDA) Investigational New Drug (IND) protocol.

  • Treating Diabetes with an Insulin Pill? Kleinberg, J. I. // Equities;Fall2006, Vol. 54 Issue 3, p22 

    The article discusses oral therapies for the treatment of diabetes developed by Oramed Pharmaceuticals Inc. The two-types of diabetes are insulin-dependant or juvenile-onset and the non-insulin dependant diabetes. Injection of insulin can be self-administered and is considered as the standard of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics